6bzw
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='6bzw' size='340' side='right' caption='[[6bzw]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='6bzw' size='340' side='right' caption='[[6bzw]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6bzw]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BZW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BZW FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6bzw]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BZW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BZW FirstGlance]. <br> |
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6bzw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bzw OCA], [http://pdbe.org/6bzw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6bzw RCSB], [http://www.ebi.ac.uk/pdbsum/6bzw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6bzw ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6bzw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bzw OCA], [http://pdbe.org/6bzw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6bzw RCSB], [http://www.ebi.ac.uk/pdbsum/6bzw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6bzw ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Elicitation of broadly neutralizing antibodies (bnAbs) is a leading strategy in rational vaccine design against antigenically diverse pathogens. Here, we studied a panel of monoclonal antibodies (mAbs) from mice immunized with the hepatitis C virus (HCV) envelope glycoproteins E1E2. Six of the mAbs recognize the conserved E2 antigenic site 412-423 (AS412) and cross-neutralize diverse HCV genotypes. Immunogenetic and structural analysis revealed that the antibodies originated from two different germline (GL) precursors and bind AS412 in a beta-hairpin conformation. Intriguingly, the anti-HCV activity of one antibody lineage is associated with maturation of the light chain (LC), whereas the other lineage is dependent on heavy-chain (HC) maturation. Crystal structures of GL precursors of the LC-dependent lineage in complex with AS412 offer critical insights into the maturation process of bnAbs to HCV, providing a scientific foundation for utilizing the mouse model to study AS412-targeting vaccine candidates. | ||
| + | |||
| + | Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.,Aleman F, Tzarum N, Kong L, Nagy K, Zhu J, Wilson IA, Law M Proc Natl Acad Sci U S A. 2018 Jun 28. pii: 1802378115. doi:, 10.1073/pnas.1802378115. PMID:29954862<ref>PMID:29954862</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6bzw" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Lk3 transgenic mice]] | ||
[[Category: Alemn, F]] | [[Category: Alemn, F]] | ||
[[Category: Law, M]] | [[Category: Law, M]] | ||
Revision as of 06:11, 11 July 2018
Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the GL precursor of the broadly neutralizing antibody AP33
| |||||||||||
